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Abstract 
Background: Tridax procumbens flavonoids (TPFs) are well known for their medicinal properties among local natives. 
Besides traditionally used for dropsy, anemia, arthritis, gout, asthma, ulcer, piles, and urinary problems, it is also used 
in treating gastric problems, body pain, and rheumatic pains of joints. TPFs have been reported to increase osteo‑
genic functioning in mesenchymal stem cells. Our previous study showed that TPFs were significantly suppressed the 
RANKL‑induced differentiation of osteoclasts and bone resorption. However, the effects of TPFs to promote osteo‑
blasts differentiation and bone formation remain unclear. TPFs were isolated from Tridax procumbens and investigated 
for their effects on osteoblasts differentiation and bone formation by using primary mouse calvarial osteoblasts.
Results: TPFs promoted osteoblast differentiation in a dose‑dependent manner demonstrated by up‑regulation of 
alkaline phosphatase and osteocalcin. TPFs also upregulated osteoblast differentiation related genes, including osteo-
calcin, osterix, and Runx2 in primary osteoblasts. TPFs treated primary osteoblast cells showed significant upregulation 
of bone morphogenetic proteins (BMPs) including Bmp‑2, Bmp‑4, and Bmp‑7. Addition of noggin, a BMP specific‑
antagonist, inhibited TPFs induced upregulation of the osteocalcin, osterix, and Runx2.
Conclusion: Our findings point towards the induction of osteoblast differentiation by TPFs and suggested that TPFs 
could be a potential anabolic agent to treat patients with bone loss‑associated diseases such as osteoporosis.
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Background
The human bone is a highly dynamic organ that maintains 
its homeostasis through a delicate balance between the 
bone-forming osteoblasts and the bone resorpting osteo-
clasts. The dynamic balance between these two types of 
cell results in bone remodeling [1–4]. Osteoporosis, a sys-
temic skeletal disease characterized by low bone mass and 
micro-architectural deterioration of bone tissue due to an 
imbalance between osteoclast mediated bone resorption 
and osteoblast mediated bone formation [5–7]. Current 
drugs used to treat osteoporosis are bone resorption inhibi-
tors including parathyroid hormones (PTH), PTH receptor 
analogues, bisphosphonates, calcitonin, estrogen and vita-
min D analogues, which maintain bone mass by inhibiting 
the function of osteoclasts [2, 8, 9]. However, the low effi-
cacy and possible side effects are the real challenge of these 
drugs to use [9]. Therefore, a sustainable drug is desirable 
to identify better and safe anabolic agents with low cyto-
toxicity that act by either increasing the osteoblasts prolif-
eration or inducing osteoblasts differentiation which can 
enhance bone formation [10, 11]. Several lines of evidence 
have shown that foods rich in flavonoids, such as fruits, 
vegetables and tea may be related to bone loss and fracture 
outcomes [12, 13]. Flavonoids are a large class of phyto-
chemicals that are widely distributed in plant foods [14–17]. 
Flavonoids have been found to decrease urinary excre-
tion of calcium and phosphate, increase osteoblast activity, 
decrease osteoclast activity, and protect against the loss of 
trabecular thickness [18–20]. Previous studies showed that 
different plant-derived flavonoid compounds can stimulate 
osteoblasts function, and inhibit osteoclasts functions either 
alone or in combination. Due to their natural occurrence 
Open Access
*Correspondence:  mssohel@yahoo.com 
1 Department of Genetic Engineering and Biotechnology, Shahjalal 
University of Science and Technology, Sylhet 3114, Bangladesh
Full list of author information is available at the end of the article
Page 2 of 8Al Mamun et al. Biol Res  (2015) 48:65 
and lack of side effects, flavonoids are considered to be safer 
than the conventional drugs replacement therapy as preven-
tive measures against various diseases including osteopo-
rosis [21]. Recently, we found the inhibitory effects of TPFs 
on osteoclast differentiation bone resorption [22]. TPFs sig-
nificantly suppressed the RANKL-induced differentiation 
of osteoclasts and formation of pits in primary osteoclastic 
cells. TPFs also decreased expression of osteoclast differen-
tiation related genes including Trap, Cathepsin K, Mmp-9, 
and Mmp-13 in primary osteoclastic cells [22].
Results
Effects of TPFs on osteoblasts differentiation
To evaluate the effects of TPFs on osteoblast differentiation, 
staining for ALP was performed as an early-differentiation 
marker of osteoblasts derived from newborn mouse calva-
ria. The results showed that TPFs enhanced the intensity of 
ALP staining and activity (Fig.  1a–c). TPFs also increased 
the mRNA expression of Alp (Fig. 1g). To determine miner-
alization, calvarial osteoblasts were cultured with TPFs for 
21  days. TPFs dramatically increased the mineralized area 
visualized by Alizarin red S staining for calcium (Fig.  1d). 
Osteocalcin in the culture media was elevated after the treat-
ment of TPFs (Fig. 1e, f). Subsequently, the mRNA expres-
sion of osteocalcin was measured as a late-stage marker of 
osteoblast differentiation. Treatment with TPFs significantly 
increased the mRNA expression of osteocalcin compared 
with control cells (Fig. 1h). These findings indicate that TPFs 
promote the osteoblast differentiation bone formation.
TPFs stimulated the expression levels of mRNAs related 
to osteoblast differentiation
After that, we investigated the effects of TPFs on 
the expression of mRNAs related to osteoblast 
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Fig. 1 The effects of TPF on osteoblast differentiation in primary osteoblast cells. The cells were treated with TPF for 6 days and stained for ALP (a), 
measured ALP activity (b, c). After then the cells were treated with TPF for 21 days, osteoblastic mineralization was determined by Alizarin red S 
staining (d) and the concentrations of osteocalcin in the culture media were measured (e, f). Effects of TPF on Alp and Osteocalcin mRNA expression 
in calvarial osteoblast cells (g, h). The data are expressed as the mean ± SD (n = 3) for each group. *p < 0.05
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differentiation. TPFs treatment for 6  days significantly 
enhanced the expression of osterix and Runx2 mRNA, 
which encode an essential transcription factors for osteo-
blast differentiation, in calvarial cells (Fig. 2a, b). To con-
firm what kinds of BMPs are involved in TPFs-induced 
osteoblast differentiation, we evaluated Bmp-2, Bmp-4 
and Bmp-7 mRNA expression level after TPFs treatment. 
The results revealed that TPFs increased the expressions 
of Bmp-2, Bmp-4 and Bmp-7 genes (Fig. 2c–e).
Noggin inhibited TPFs‑induced osteoblast differentiation
We confirmed the effects of noggin, a BMP specific 
antagonist on TPFs-induced osteoblast differentia-
tion using calvarial osteoblastic cells. Noggin inhibited 
TPFs-induced ALP activity (Fig.  3a–c) and mineraliza-
tion (Fig. 3d–f) in calvarial osteoblastic cells. Noggin also 
inhibited TPFs-induced expression of Alp, osteocalcin, 
osterix, and Runx2 mRNA level in calvarial osteoblastic 
cells (Fig. 4a–d).
Discussion
In the present study, we demonstrated that TPFs stimu-
lated osteoblast differentiation in the calvarial osteo-
blastic cells isolated from the calvariae of newborn mice 
(primary osteoblastic cells). Treatment of primary osteo-
blasts with TPFs results overexpression of the Alp gene 
and increased ALP activity (Fig.  1). Besides upregula-
tion of ostocalcin, TPFs treated osteoblasts also showed 
significant upregulation of osterix, Bmp-2, Bmp-4 and 
Bmp-7 compared to control group (Figs.  1h, 2). Osteo-
blasts play a crucial role in the bone formation, differenti-
ating from mesenchymal stem cells is regulated by many 
growth factors including BMPs, Runx2 and Osterix [3, 
4, 23]. Role of these growth factors in osteoblast differ-
entiation and bone formation is well known. Runx2 and 
osterix deficient mice lacked bone formation because of 
the maturation arrest of osteoblasts [6, 24–26]. In addi-
tion, several lines of evidence have shown that the BMPs 
expression levels are up-regulated during bone regenera-
tion and that BMPs stimulate osteoblast differentiation 
and bone formation [27–33]. The osteogenic differen-
tiation is obtained through induction of ALP activity and 
expression of bone matrix protein osteocalcin [4, 34].
Traditional medicines play an important role in health 
services around the globe. The rational design of novel 
drugs from traditional medicine offers new prospects in 
modern healthcare [35–37]. Dietary habits are known to 
play a role in the prevention of osteoporosis. Some stud-
ies investigated that the potential benefits of fruits, veg-
etables, tea, and herbs on bone metabolism [38]. It was 
showed that the consumption of vegetables and fruits 
inhibited bone resorption in rats better than meat or 
milk. The meat and milk products commonly believed to 
be beneficial for bone health [39]. In Bangladesh, Tridax 
procumbens flavonoids are made into paste and applied 
on fresh cuts [40]. Decoctions of the flavonoids from 
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Fig. 2 Effects of TPF on Osterix Runx2, Bmp2, Bmp4 and Bmp7 mRNA expression in calvarial cells (a–e). The cells were cultured for 6 days in the 
presence or absence of TPF treatment. The data are expressed as the mean ± SD (n = 3) for each group. *p < 0.05
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Tridax procumbens leaves and root bark have been tradi-
tionally used for treatment of dropsy, anaemia, arthritis, 
gout, ulcer, piles, and urinary problems [41]. TPFs also 
used in the treatment for fever, typhoid, cough, diar-
rhea, gastric problems, body pain, and rheumatic pains 
of joints [42, 43]. TPFs have antimicrobial effects such as 
antibacterial, antifungal and antiviral [44–46]. Recently, 
our study showed that TPFs can inhibit the osteoclasts 
differentiation and bone resorption [22]. This study 
investigated the direct effects of TPFs on induced-oste-
oblasts differentiation in the primary osteoblasts. This 
result suggested that TPFs is a potent agent stimulating 
osteoblasts differentiation of calvarial osteoblastic cells. 
Osteoblast maturation is a key step in the process of bone 
development [47, 48]. Therefore, TPFs may promote 
bone formation by stimulating osteoblast maturation, 
rather than by its cytotoxicity. We have shown that TPFs 
induced osterix, and Runx2 mRNA expression in calvarial 
cells (Fig. 2). TPFs induced increase in the Runx2 mRNA 
expression level may be involved in induced stimulatory 
effects on osteoblasts differentiation of calvarial osteo-
blastic cells. However, further clarification is necessary 
to get an insight that is these TPFs stimulated osteoblast 
differentiation occurred via Runx2-dependent or Runx2-
independent pathways.
Conclusions
These studies will provide important information for 
identifying the target molecules of TPFs in osteoblast dif-
ferentiation. In summary, this is the first study to show 
that a natural compound, TPFs, isolated from Tridax 
procumbens stimulatory effects on osteoblast differentia-
tion mineralization. These results suggest that TPFs is a 
candidate anabolic agent for stimulating bone formation. 
This effect of TPFs treatment will be useful and might be 
a promising therapeutic agent for bone diseases such as 
bone repair and osteoporosis.
Methods
Plant materials
The Tridax procumbens plant was collected from the 
northeast part of Bangladesh. After its identification 
by Professor Dr. Anwar Ul Islam, Department phar-
macy, Rajshahi University, Bangladesh, a voucher speci-
men (Ref. GEB09032014/3) was submitted to the Plant 
Biotechnology laboratory, Department of Genetic 
a
b c
d
e f
Fig. 3 The effects of TPF with noggin on osteoblast differentiation in primary osteoblast cells. The cells were treated with TPF for 6 days and stained 
for ALP (a), measured ALP activity (b, c). After then the cells were treated with TPF for 21 days, osteoblastic mineralization was determined by 
Alizarin red S staining (d) and the concentrations of osteocalcin in the culture media were measured (e, f). The data are expressed as the mean ± SD 
(n = 3) for each group. *p < 0.05
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Engineering and Biotechnology, Shahjalal University of 
Science and Technology, Sylhet-3114, Bangladesh. The 
experimental procedures were reviewed and approved by 
the Ethical Committee of Shahjalal University of Science 
and Technology, Sylhet, Bangladesh.
Sample preparation
Different plant parts of Tridax procumbens (root, stem, 
leaf, and flowers) were separately shade dried, finely 
powdered using a blender, and subjected to extraction 
of TPFs in following the method as described else-
where [22, 43, 49] with some modifications. Briefly, 
two hundred grams of each finely powdered sam-
ple was Soxhlet extracted with 80  % hot methanol 
(1000 ml) on a water bath for 24 h and filtered. Filtrate 
was re-extracted successively with petroleum ether, 
ethyl ether and ethyl acetate using separating funnel. 
Petroleum ether fractions were discarded as being rich 
in fatty substances, whereas ethyl ether and ethyl ace-
tate fractions were analyzed for free and bound flavo-
noids, respectively. Ethyl acetate fraction of each of the 
samples was hydrolyzed by refluxing with 7  % H2SO4 
for 2 h for removal of bounded sugars from the flavo-
noids. Resulting mixture was filtered and filtrate was 
extracted with ethyl acetate in separating funnel. Ethyl 
acetate extract thus obtained was washed with distilled 
water to neutrality. Ethyl ether and ethyl acetate frac-
tions flavonoids were dried and weighed. The extracts 
were stored at 4  °C for farther used and were re-sus-
pended in their respective.
Total flavonoids determination
Total flavonoids content of each extract was deter-
mined by aluminum chloride as described elsewhere 
[50, 51] with some modifications. Briefly, plant extracts 
(0.5 ml of 1:10 g/ml) were separately mixed with 1.5 ml 
a b
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Fig. 4 Effects of TPF with noggin on Alp, Osteocalcin, Osterix and Runx2, mRNA expression in calvarial cells (a–d). The cells were cultured for 6 days 
in the presence or absence of TPF treatment. The data are expressed as the mean ± SD (n = 3) for each group. *p < 0.05
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of methanol, 0.1 ml of 10 % aluminum chloride, 0.1 ml 
of 1 M potassium acetate and 2.8 ml of distilled water. It 
remained at room temperature for 30 min. The absorb-
ance of the reaction mixture was measured at 415  nm 
with a spectrophotometer, and quercetin was used as 
a standard for calibration curve. Total flavonoids val-
ues are expressed in terms of mg equal quercetin in 1 g 
powder.
Reagents
Penicillin, streptomycin, α-minimum essential medium 
(α-MEM), and fetal bovine serum (FBS) were purchased 
from Invitrogen (Carlsbad, CA, USA). Recombinant 
soluble human M-CSF, human RANKL, collagenase 
A, dispase, alizarin red, fast blue BB salt, naphthol 
AS-MX phosphate, Dulbecco’s modified Eagle’s medium 
(DMEM), and all other reagents were purchased from 
Sigma-Aldrich (St. Louis, MO, USA).
Cell culture
Mice calvarial osteoblasts were obtained from neonatal 
mice as described elsewhere [52]. Briefly, calvaria from 
fifteen 1-day-old C57BL/6 mice were pooled. Follow-
ing surgical isolation from the skull and the removal of 
sutures and adherent mesenchymal tissues, the calva-
ria were subjected to sequential digestions at 37 °C in a 
solution containing 0.1 % dispase and 0.1 % collagenase 
P. The cells from the second to fifth digestions were 
collected, centrifuged, resuspended, and isolated cells 
were cultured in a T-25 cm2 flask in α-MEM containing 
10 % FBS and 1 % penicillin/streptomycin. Cell culture 
medium was replaced in every 3 days. When osteoblast 
cells reached 80 % confluence, they were harvested with 
0.25 % trypsin–EDTA solution. The cells were seeded in 
96-well plates and 6-well plates at a density of 1 × 104 
and 1  ×  106 cells/well, respectively, and cultured in 
a humidified atmosphere of 5  % CO2 and 95  % air, at 
37 °C.
Measurement of alkaline phosphatase (ALP) activity
After cultured in 6-well plates with TPFs at concentra-
tions of 0, 50, and 100  ng/ml for 48  h, osteoblasts cells 
were analyzed for ALP activity by ALP staining and 
ALP activity assay. For ALP staining, cells were rinsed 
twice with phosphate-buffered saline (PBS), fixed with 
2 % paraformaldehyde. ALP substrate mixture was then 
added and incubated for 15 min for color development. 
For ALP activity assay, cell layers were scraped off culture 
plates in scraping buffer. Cell pellets were collected after 
a quick spin. Cells were then lysed in ALP lysis buffer 
and subjected to 3 freeze–thaw cycles. After centrifuge 
at 14,000  rpm for 5  min, supernatant was collected. 
20  μl supernatant from each sample was added to each 
well in duplicates in a 96-well plate and incubated with 
an assay mixture of p-nitrophenyl phosphate. Plates were 
then scanned for spectrophometric analysis using a plate 
reader (T60 U, PG Instruments Ltd., England). Absorb-
ance was measured at 405  nm every 5  min for 30  min. 
Activity was calculated of ALP staining positive cells 
using an image analyzing system (KS 400; Carl Zeiss, 
Jean, Germany) were performed on culture day 6, as pre-
viously described [52, 53].
Assays of osteoblast maturation
Osteoblast maturation was determined by evaluating 
cell mineralization using the Alizarin red S dye stain-
ing protocols. Osteoblasts were treated with TPFs at 
concentrations of 0, 50, and 100  ng/ml for 21  days. 
After drug treatment, osteoblasts were washed with 
ice-cold phosphate-based saline (PBS) buffer (0.14  M 
NaCl, 2.6  mM KCl, 8  mM Na2HPO4, and 1.5  mM 
KH2PO4) and then fixed in ice-cold 10 % formalin for 
20  min. For the Alizarin red S dye-staining protocol, 
the fixed osteoblasts were rinsed thoroughly and then 
incubated in 1 % alcian blue pH 2.5 for 12 h. The sec-
tions were then incubated in Alizarin red S for 8 min, 
dehydrated briefly in xylene and cover slipped in 
per-mount. Mineralized nodules were visualized and 
counted using an image analyzing system (KS 400; Carl 
Zeiss, Jean, Germany) were performed on culture day 
21, as previously described [52, 53]. Each experiment 
was performed in duplicate wells and repeated three 
times.
Reverse transcriptase‑polymerase chain reaction analysis
Osteoblasts cells were seeded in 6-well plates at a den-
sity of 1 × 106 cells/well. After 6-day culture, cells were 
treated with TPFs at concentrations of 0, 50, and 100 ng/
ml for 48 h. Total RNA from the cells of each well was iso-
lated, respectively using NucleoSpin (Macherey–Nagel, 
Duren, Germany). RNA aliquots were reverse tran-
scribed to complementary DNAs by using an oligo (dT) 
primer (Roche), deoxynucleotide triphosphate (dNTP), 
and Moloney murine leukemia virus (M-MuLV) reverse 
transcriptase (Fermentas, Hanover, MD, USA). The com-
plementary DNA products were subjected to PCR ampli-
fication with gene-specific primers for mouse osteocalcin, 
Runx2, osterix, Alp, Bmp-2, Bmp-4, and Bmp-7 (Table 1). 
Real-time RT-PCR amplification was performed using a 
LightCycler System (Roche) with a Platinum SYBR Green 
qPCR SuperMix UDG kit (Invitrogen, Carlsbad, CA, 
USA).
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Statistical analyses
We used analysis of variance with an F test, followed by a 
t test. P values less than 0.05 were considered significant. 
The data are presented as mean ± standard deviation val-
ues of independent replicates.
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